Company intelligence / Profile preview

Changchun Institute of Biological Products Co., Ltd.

Changchun City, Jilin Province, 中国(China)gojilin.gov.cn ↗
Ownership
Private
Employees
~900
Development stage
Commercial
01

Overview

CCIBP has a long track record as one of China’s leading vaccine manufacturers. Its quadrivalent influenza vaccine has been marketed for over two decades with more than 90 million doses sold and WHO prequalification achieved. The company also produces approved hepatitis A and rabies vaccines. It continues to develop new prophylactic vaccines targeting emerging infectious diseases such as tick-borne encephalitis and viral hemorrhagic fevers. Clinical trials are ongoing for next-generation influenza formulations and other indications.

Therapeutic areas
ImmunologyInfectious Diseases
Modalities
Prophylactic vaccinesinactivated vaccineslive attenuated vaccinesbiosimilarsinterferons
Industry
Biotech
02

Drug pipeline

9 assets

Quadrivalent influenza split vaccine (Weiguang Biological Products)

Approved

8 more assets in the full pipeline.

Request access →
03

Partnerships

Parent company Sinopharm/CNBG provides extensive distribution channels domestically/internationallyInternational collaborations via WHO prequalification processes for global supply

Beyond the preview

Go deeper on Changchun Institute of Biological Products Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Changchun Institute of Biological Products Co., Ltd..

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call